Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071843 | 0.92 | FGFR1 (0.50) | FGFR1KCNH2KDRALDH1A1MAPT | |
| SCHEMBL22071823 | 0.90 | FGFR1 (0.48) | FGFR1KCNH2KDRALDH1A1MAPT | |
| SCHEMBL19781598 | 0.85 | FGFR1 (0.55) | FGFR1KCNH2KDRALDH1A1MAPT | |
| SCHEMBL19781253 | 0.85 | FGFR1 (0.60) | FGFR1KCNH2KDRALDH1A1MAPT | |
| SCHEMBL19781511 | 0.82 | FGFR1 (0.59) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19781537 | 0.79 | KCNH2 (0.55) | FGFR1KCNH2KDRALDH1A1MAPT | |
| SCHEMBL19781136 | 0.78 | BCL2 (0.38) | FGFR1MAPT | |
| SCHEMBL19781769 | 0.77 | FGFR1 (0.56) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15213070 | 0.76 | FGFR1 (0.67) | FGFR1KDRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22032815 | 0.76 | GABRA1 (0.39) | FGFR1KCNH2KDRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | HAVCR2, ZC3HAV1, CD4 | FGFR1 4440/4885KCNH2 4365/4885KDR 3639/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | FGFR1 3928/4885KCNH2 107/4885KDR 3283/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | FGFR1 3928/4885KCNH2 107/4885KDR 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.